Deniz Publication
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513


Publisher: Deniz Publication
ARTICLE
Year: 2014   |   Volume: 3   |   Issue: 3   |   Page: 200-207     View issue

Pomalidomide: A novel imunomodulatory drug for the treatment of relapsed and refractory multiple myeloma


, , ,
Abstract

Introduction: The novel agents bortezomib and lenalidomide have demonstrated improved clinical outcomes in multiple myeloma (MM), yet most relapsed MM patients will become refractory to therapy. Methods: Pomalidomide is a second generation immunomodulatory agent that has been recently approved in the USA for the treatment of relapsed and refractory MM after two prior therapies, including lenalidomide and bortezomib. Results: Pomalidomide has several potential mechanisms of action which include anti-angiogenic effects, immunomodulation, an effect on the myeloma tumor microenvironment and the protein cereblon. Discussion: Several trials demonstrate the efficacy and safety of this novel compound in relapsed and refractory MM, including subjects refractory to lenalidomide and bortezomib. In the following review article, we discuss the role of pomalidomide as a new clinical treatment option for MM.

Cite this article
Vancouver
Bajaj N, Shaaban H, Maroules M, Guron G. Pomalidomide: A novel imunomodulatory drug for the treatment of relapsed and refractory multiple myeloma. Clin Cancer Investig J. 2014;3(3):200-7. https://doi.org/10.4103/2278-0513.132109
APA
Bajaj, N., Shaaban, H., Maroules, M., & Guron, G. (2014). Pomalidomide: A novel imunomodulatory drug for the treatment of relapsed and refractory multiple myeloma. Clinical Cancer Investigation Journal, 3(3), 200-207. https://doi.org/10.4103/2278-0513.132109

Copyright © 2024 Clinical Cancer Investigation Journal. Authors retain copyright of their article if they are accepted for publication.
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513